191 related articles for article (PubMed ID: 25425641)
1. Use of chimeras, point mutants, and molecular modeling to map the antagonist-binding site of 4,4',4″,4‴-(carbonylbis-(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakisbenzene-1,3-disulfonic acid (NF449) at P2X1 receptors for ATP.
Farmer LK; Schmid R; Evans RJ
J Biol Chem; 2015 Jan; 290(3):1559-69. PubMed ID: 25425641
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop.
El-Ajouz S; Ray D; Allsopp RC; Evans RJ
Br J Pharmacol; 2012 Jan; 165(2):390-400. PubMed ID: 21671897
[TBL] [Abstract][Full Text] [Related]
3. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups.
Hausmann R; Rettinger J; Gerevich Z; Meis S; Kassack MU; Illes P; Lambrecht G; Schmalzing G
Mol Pharmacol; 2006 Jun; 69(6):2058-67. PubMed ID: 16551782
[TBL] [Abstract][Full Text] [Related]
4. Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region.
Huo H; Fryatt AG; Farmer LK; Schmid R; Evans RJ
J Biol Chem; 2018 Aug; 293(33):12820-12831. PubMed ID: 29997254
[TBL] [Abstract][Full Text] [Related]
5. Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist.
Rettinger J; Braun K; Hochmann H; Kassack MU; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
Neuropharmacology; 2005 Mar; 48(3):461-8. PubMed ID: 15721178
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt].
Hechler B; Magnenat S; Zighetti ML; Kassack MU; Ullmann H; Cazenave JP; Evans R; Cattaneo M; Gachet C
J Pharmacol Exp Ther; 2005 Jul; 314(1):232-43. PubMed ID: 15792995
[TBL] [Abstract][Full Text] [Related]
7. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.
Braun K; Rettinger J; Ganso M; Kassack M; Hildebrandt C; Ullmann H; Nickel P; Schmalzing G; Lambrecht G
Naunyn Schmiedebergs Arch Pharmacol; 2001 Sep; 364(3):285-90. PubMed ID: 11521173
[TBL] [Abstract][Full Text] [Related]
8. Ectodomain lysines and suramin block of P2X1 receptors.
Sim JA; Broomhead HE; North RA
J Biol Chem; 2008 Oct; 283(44):29841-6. PubMed ID: 18765669
[TBL] [Abstract][Full Text] [Related]
9. P2X receptor chimeras highlight roles of the amino terminus to partial agonist efficacy, the carboxyl terminus to recovery from desensitization, and independent regulation of channel transitions.
Allsopp RC; Farmer LK; Fryatt AG; Evans RJ
J Biol Chem; 2013 Jul; 288(29):21412-21421. PubMed ID: 23740251
[TBL] [Abstract][Full Text] [Related]
10. NF449, a novel picomolar potency antagonist at human P2X1 receptors.
Hülsmann M; Nickel P; Kassack M; Schmalzing G; Lambrecht G; Markwardt F
Eur J Pharmacol; 2003 May; 470(1-2):1-7. PubMed ID: 12787824
[TBL] [Abstract][Full Text] [Related]
11. Cysteine scanning mutagenesis (residues Glu52-Gly96) of the human P2X1 receptor for ATP: mapping agonist binding and channel gating.
Allsopp RC; El Ajouz S; Schmid R; Evans RJ
J Biol Chem; 2011 Aug; 286(33):29207-29217. PubMed ID: 21690089
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist.
Kassack MU; Braun K; Ganso M; Ullmann H; Nickel P; Böing B; Müller G; Lambrecht G
Eur J Med Chem; 2004 Apr; 39(4):345-57. PubMed ID: 15072843
[TBL] [Abstract][Full Text] [Related]
13. Identification of atropine- and P2X1 receptor antagonist-resistant, neurogenic contractions of the urinary bladder.
Kennedy C; Tasker PN; Gallacher G; Westfall TD
J Neurosci; 2007 Jan; 27(4):845-51. PubMed ID: 17251425
[TBL] [Abstract][Full Text] [Related]
14. A fluorescent approach for identifying P2X1 ligands.
Ruepp MD; Brozik JA; de Esch IJ; Farndale RW; Murrell-Lagnado RD; Thompson AJ
Neuropharmacology; 2015 Nov; 98():13-21. PubMed ID: 26026951
[TBL] [Abstract][Full Text] [Related]
15. Lipid raft association and cholesterol sensitivity of P2X1-4 receptors for ATP: chimeras and point mutants identify intracellular amino-terminal residues involved in lipid regulation of P2X1 receptors.
Allsopp RC; Lalo U; Evans RJ
J Biol Chem; 2010 Oct; 285(43):32770-32777. PubMed ID: 20699225
[TBL] [Abstract][Full Text] [Related]
16. Identification of an intersubunit cross-link between substituted cysteine residues located in the putative ATP binding site of the P2X1 receptor.
Marquez-Klaka B; Rettinger J; Bhargava Y; Eisele T; Nicke A
J Neurosci; 2007 Feb; 27(6):1456-66. PubMed ID: 17287520
[TBL] [Abstract][Full Text] [Related]
17. Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors.
Soto F; Lambrecht G; Nickel P; Stühmer W; Busch AE
Neuropharmacology; 1999 Jan; 38(1):141-9. PubMed ID: 10193905
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cultured dorsal root ganglion neuron P2X receptors.
Grubb BD; Evans RJ
Eur J Neurosci; 1999 Jan; 11(1):149-54. PubMed ID: 9987019
[TBL] [Abstract][Full Text] [Related]
19. The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.
Horner S; Menke K; Hildebrandt C; Kassack MU; Nickel P; Ullmann H; Mahaut-Smith MP; Lambrecht G
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):1-13. PubMed ID: 16158305
[TBL] [Abstract][Full Text] [Related]
20. Cysteine substitution mutagenesis and the effects of methanethiosulfonate reagents at P2X2 and P2X4 receptors support a core common mode of ATP action at P2X receptors.
Roberts JA; Digby HR; Kara M; El Ajouz S; Sutcliffe MJ; Evans RJ
J Biol Chem; 2008 Jul; 283(29):20126-36. PubMed ID: 18487206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
